INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 49m ago
HOUSE PTR9m ago
SEC 13F9m ago
ROBINHOOD CHAIN9m ago
SEC FORM 4/Option exerciseVerified data

Goodrich Katherine reported TARS

Director · Tarsus Pharmaceuticals, Inc. · Common Stock

Side
M
Value
—
Shares
2,954
Price
—
Executed
Jun 12, 2026
Disclosed
Jun 16, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 12 executedJun 16, 2026 disclosed

TARS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 132.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TARS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    20
    AR
    Azamian Bobak R.Director, President/CEO and Board Chair
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$265K
    2,900 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    28
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$135K
    1,590 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    32
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$143K
    1,590 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    27
    NS
    Neervannan SeshadriChief Operating Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$388K
    4,564 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    31
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$458K
    5,387 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    20
    AR
    Azamian Bobak R.Director, President/CEO and Board Chair
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$641K
    7,100 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    35
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$485K
    5,386 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    9
    GD
    Goldberg Andrew D.Director
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    3,837 sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    5
    GK
    Goodrich KatherineDirector
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    2,417 sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    GD
    Goldberg Andrew D.Director
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    2,417 sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    5
    GK
    Goodrich KatherineDirector
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    3,837 sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    18
    AR
    Azamian Bobak R.Director, President/CEO and Board Chair
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$335K
    5,418 sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    18
    AR
    Azamian Bobak R.Director, President/CEO and Board Chair
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$281K
    4,582 sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    25
    GK
    Goodrich KatherineDirector
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$183K
    2,954 sh
    		Jun 15, 2026Jun 17, 2026
    traded Jun 15, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GK
    Goodrich KatherineDirector
    TARSTarsus Pharmaceuticals, Inc.
    Option exercise
    		M—
    2,954 sh
    		Jun 12, 2026Jun 16, 2026
    traded Jun 12, 2026
    		+4dSEC FORM 4

    Evidence

    42
    MA
    Mottiwala AzizChief Commercial Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale
    		SELL$298K
    4,330 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    36
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale
    		SELL$26K
    375 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    32
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale
    		SELL$26K
    379 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    32
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale
    		SELL$26K
    390 sh
    		Mar 19, 2026Mar 19, 2026
    traded Mar 19, 2026
    		+0dSEC FORM 4

    Evidence

    42
    WC
    Whitfield Dianne C.Chief Human Resources Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale
    		SELL$280K
    4,071 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002044770-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 12, 2026
    Published
    Jun 16, 2026
    Ingested by INSIDER
    Nov 5, 03:52 UTC
    Last re-read
    Nov 5, 03:52 UTC

    Extracted facts

    Filer
    Goodrich Katherine
    Role
    Director
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Tarsus Pharmaceuticals, Inc.
    Ticker
    TARS
    Shares
    2,954
    Execution date (reported)
    Jun 12, 2026
    Owned after transaction
    5,187 shares
    Days from execution to publication
    4

    What this establishes

    Goodrich Katherine filed this Form 4 reporting a option exercise of TARS on Jun 12, 2026. It became public on Jun 16, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Goodrich Katherinecik:0002044770
    Issuer
    Tarsus Pharmaceuticals, Inc.cik:0001819790

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.